Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02672098 · ClinicalTrials.gov registry record · Phase 1
Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
A Phase 1 study, sponsored by Loma Linda University.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02672098 is a Phase 1 study that has completed, run by Loma Linda University. The registered enrollment target is 3 participants.
The verdict
NCT02672098, a Phase 1 study, has completed, sponsored by Loma Linda University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a phase I prospective study with the primary objective to compare the efficacy and safety of Surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of recurrent ovarian, primary peritoneal or fallopian tube cancers. Eligible patients consenting to this protocol will undergo their scheduled surgical procedure. After surgical cytoreduction to a residual disease ≤ 2.5 mm, a single dose of carboplatin (800 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen. HIPEC will be continued for 90 minutes in the hyperthermic phase (41°C-43°C). At 4-6 weeks after CRS, patients will go on to receive 6 cycles of standard IV platinum-based chemotherapy. The proportion of patients who are without evidence of recurrence will be assessed at 6, 9, 12 and 18 months after the day of surgery.
Interventions
- DRUG Carboplatin
- PROCEDURE Hyperthermic intraperitoneal chemotherapy (HIPEC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-07-14 |
| Est. Completion | 2023-04-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02672098
The ClinicalTrials.gov registry entry for NCT02672098 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT02672098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02672098 about?
NCT02672098 is a clinical study titled "Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer". This is a phase I prospective study with the primary objective to compare the efficacy and safety of Surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of recurrent ovarian, primary peritoneal or fallopian tube cancers. Eligible patients consenting to thi...
What is the current status of trial NCT02672098?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2016-07-14. Estimated completion is 2023-04-19.
What interventions are being tested in trial NCT02672098?
The interventions under investigation include: Carboplatin (DRUG), Hyperthermic intraperitoneal chemotherapy (HIPEC) (PROCEDURE).
Who is sponsoring clinical trial NCT02672098?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.